Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Greenwich Lifesciences Inc (NQ: GLSI ) 13.66 +0.57 (+4.35%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Greenwich Lifesciences Inc < Previous 1 2 Next > Greenwich LifeSciences Inc. (NASDAQ: GLSI) Near the Top of Equities by Percentage Gain on 2/14 February 14, 2024 Via Investor Brand Network Greenwich LifeSciences Provides Year End Update December 29, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023 December 01, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial August 11, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial August 03, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Provides Financing Strategy & Corporate Update July 28, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed July 12, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Announces Suspension of Share Repurchase Program July 11, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences to Resume Stock Repurchase Program May 23, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting May 23, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences April 20, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer April 19, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference February 03, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01 February 01, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year January 24, 2022 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster December 15, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology December 09, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences to Participate in Multiple Interviews and Conferences December 08, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial December 07, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2 December 06, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report November 18, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference November 17, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference November 11, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01 November 10, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts November 09, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston September 28, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference September 27, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference September 23, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference September 13, 2021 From Greenwich LifeSciences, Inc. Via Business Wire Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments September 09, 2021 From Greenwich LifeSciences, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
